Disease or drug association providing system for digital twins with genetic information screened by artificial intelligence

Abstract

The present disclosure relates to a disease or drug association providing system for a digital twin with genetic information screened by an artificial intelligence. To this end, provided is the disease or drug association providing system for a digital twin with genetic information screened by an artificial intelligence, the system including, a clinical information generating unit including, (i-1) a genetic informatics pipeline unit which sequentially outputs genetic sequencing data of a patient in a predetermined unit, (i-2) a predicted candidate group screening AI unit which screens a predicted candidate group for the disease and a predicted candidate group for the drug with respect to the genetic information output from the genetic informatics pipeline unit, (i-3) a dimensionality reduction AI unit which reduces a size of the genetic information, and (i-4) a genetic informatics integration unit which receives and integrates the genetic information trained by the predicted candidate group screening AI unit and the dimensionality reduction AI unit from the genetic informatics pipeline unit, (ii) a patient's digital twin file which is virtually generated based on information about a body of the patient, and the predicted candidate group for the disease and the predicted candidate group for the drug received from the genetic informatics integration unit, (iii) a disease information table which receives and stores information about a disease from the outside, (iv) a drug information table which receives and stores information about a drug from the outside, and (v) a controller which calculates and provides an association with the disease information table about the genetic information of the digital twin file and an association with the drug information table about the genetic information of the digital twin file.

Dependencies are inferred from the claim text.